Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males or females, aged ≥40 years~* Body Mass Index (BMI) ≤ 40.0 kg/m2~* Diagnosis of primary OA of the Index knee, with symptoms present for at least 6 months~* OA severity Grade 2 or 3 (based on Kellgren Lawrence Grading Scale)~* Unsatisfactory pain relief from at least 2 prior standard OA treatments~* Qualifying pain in the Index knee during the baseline period~* Ambulatory (without the need for a cane/other walking aide)~* Female subjects willing to use highly effective birth control methods to prevent pregnancy~* Willing and able to comply with study procedures and restrictions, including abstaining from use of restricted medications.~Key Exclusion Criteria:~* OA of the Index knee due to acute injury or trauma, or unstable joint~* X-ray evidence of chondrocalcinosis~* Diagnosed or suspected ipsilateral hip OA~* Knee pain that is not attributable to OA of the knee~* Any other disorders that impact mobility, strength or sensation, or are a co-existent source of pain or inflammation that interfere with assessment of knee pain and function~* History of infection in the Index knee~* Skin breakdown on the Index knee where the injection will take place~* Total Knee Replacement, or any other surgery (including arthroscopy) for the Index knee within prior 12 months, or planned surgery during the study~* Total Knee Replacement Surgery of the non-Index knee within prior 6 months, or planned surgery (any location) during the study that would require a restricted medication~* IA injection of corticosteroids in any joint within prior 3 months or IA injection of extended-release corticosteroids in any joint within prior 6 months~* IA injection in the Index knee of platelet rich plasma, or other prolotherapy within prior 3 months, or hyaluronic acid within prior 6 months~* Recent, current or planned use of corticosteroids for any indication (except for permitted uses)~* Recent, current or planned use of prohibited medications (including analgesics, marijuana, investigational drugs and devices, immunosuppressive therapy), or unwilling or unable to stop using prohibited medications during the study.~* Conditions including: sarcoidosis, amyloidosis, osteomyelitis, Cushing's Syndrome, hepatic or renal disease, Psychotic disorder, bipolar disorder, symptomatic depressive or anxiety disorders.~* Current malignancy of any type, or history of a malignancy within prior 12 months~* Active or quiescent systemic fungal, bacterial (including tuberculosis) viral (including HIV, Hepatitis B or C) or parasitic infections, or ocular herpes simplex, or any recent infection requiring IV or oral antibiotics~* Laboratory results indicative of adrenal insufficiency, diabetes or renal or hepatic disease.~* Positive urine drug screen for a substance of abuse~* Females who are pregnant, lactating~* Known or suspected hypersensitivity or contraindication to ingredients in the study drug

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EP-104IAR 25 mg (Type: EXPERIMENTAL): A single use intra-articular injection containing 25 mg of EP-104IAR
- Placebo (vehicle) (Type: PLACEBO_COMPARATOR): A single use intra-articular injection containing no active ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).